Today: 21 May 2026
Browse Category

NASDAQ:RAPT 20 January 2026 - 22 January 2026

GSK share price steadies as $2.2bn RAPT deal lands amid fresh U.S. vaccine-policy risk

GSK share price steadies as $2.2bn RAPT deal lands amid fresh U.S. vaccine-policy risk

GSK shares rose 0.1% in early London trading as investors assessed the $2.2 billion acquisition of RAPT Therapeutics and changes to ViiV Healthcare’s ownership. The deal brings ozureprubart, a mid-stage food-allergy drug, into GSK’s pipeline. Pfizer will exit ViiV, with Shionogi raising its stake to 21.7%. Uncertainty over U.S. vaccine policy clouds the outlook ahead of GSK’s Feb. 4 results.
22 January 2026
···
GSK stock slips after $2.2 billion RAPT deal — what investors watch before the open

GSK stock slips after $2.2 billion RAPT deal — what investors watch before the open

GSK’s U.S.-listed shares fell 1.2% to $47.65 premarket after it agreed to buy RAPT Therapeutics for $2.2 billion, paying a 65% premium for rights to a mid-stage food allergy drug. The deal, led by new CEO Luke Miels, comes as GSK faces pressure to offset losses from expiring HIV drug patents. Pfizer will exit the ViiV Healthcare joint venture, with Shionogi raising its stake to 21.7%.
21 January 2026
···
RAPT Therapeutics stock jumps 64% as GSK agrees $2.2 billion takeover at $58 a share

RAPT Therapeutics stock jumps 64% as GSK agrees $2.2 billion takeover at $58 a share

Rapt Therapeutics shares surged 64% to $57.57 in after-hours trading after GSK agreed to acquire the company for $58 a share in cash, valuing Rapt at about $2.2 billion. The deal centers on ozureprubart, a long-acting anti-IgE antibody. GSK plans to launch a tender offer within 10 business days. Closing depends on a majority of Rapt shares being tendered and U.S. antitrust clearance.
21 January 2026
···
RAPT stock price jumps as GSK strikes $2.2 billion buyout for food allergy drug

RAPT stock price jumps as GSK strikes $2.2 billion buyout for food allergy drug

RAPT Therapeutics shares soared 64% to $57.54 after GSK announced a $58-per-share cash acquisition, valuing the biotech at $2.2 billion. The deal centers on ozureprubart, an experimental anti-IgE drug for food allergies. GSK plans to launch a tender offer within 10 business days, pending antitrust review. RAPT’s stock hovered just below the offer price as investors watched for regulatory developments.
20 January 2026
···

Stock Market Today

  • Shell Investment Narrative Shifts Amid Mixed Analyst Valuations and Operational Updates
    May 21, 2026, 3:53 PM EDT. Shell (LSE:SHEL) sees a mixed analyst response as its fair value estimate rises to £38.17 from £37.02. Bullish upgrades cite 6% higher net income forecasts post-ARC Resources acquisition, with Jefferies and HSBC raising targets reflecting improved cash flow and upstream growth visibility. Conversely, Morgan Stanley, BNP Paribas, and others express caution over execution risk and commodity volatility, issuing downgrades. Operational challenges include a force majeure declaration on LNG contracts due to Qatar production shutdowns. Shell repurchased 270 million shares worth over US$10 billion in the latest buyback program, underpinning shareholder returns. Market watchers should balance stronger cash projections against ongoing commodity and macro risks amid geopolitical uncertainties.

Latest articles

RBC Stock Heads Toward Earnings With Tougher Weeks Ahead

RBC Stock Heads Toward Earnings With Tougher Weeks Ahead

21 May 2026
Royal Bank of Canada shares climbed 1.46% to C$261.09 in Toronto Thursday, outpacing the S&P/TSX Composite ahead of its May 28 earnings release. Visible Alpha estimates see net income up 19% to C$5.4 billion. Analyst calls diverged, with BofA raising its price target and Raymond James downgrading the stock to neutral. RBC shares have gained nearly 49% over the past year.
Sandisk Stock Jumps Again as AI Demand Fuels Memory Squeeze

Sandisk Stock Jumps Again as AI Demand Fuels Memory Squeeze

21 May 2026
Sandisk shares surged about 10% Thursday, trading at $1,533.00 by 2:52 p.m. EDT after management said NAND flash supply would stay tight. Citi raised its price target to $2,025. Western Digital and Micron also gained. Sandisk reported fiscal Q3 revenue of $5.95 billion, up 97% sequentially, with net income of $3.62 billion.
Spotify jumps after Universal AI deal, 2030 outlook

Spotify jumps after Universal AI deal, 2030 outlook

21 May 2026
Spotify shares rose 13.5% to $491.92 Thursday after announcing a new AI music licensing deal with Universal Music Group and unveiling growth targets at its investor day in New York. The company projected mid-teens annual revenue growth through 2030, gross margin of 35–40%, and operating margin above 20%. Spotify reported 761 million monthly active users in April.
Go toTop